Weekly Recap | Oruka Therapeutics +2.79%, most brokers rate it buyWeekly Review·Sep 19, 2026 at 06:39 AMORKA+3.55%
Oruka Therapeutics Drops 7.9% After Stock OfferingMovers Alert·Apr 29, 2026 at 04:42 PMORKA+3.55%LABU+7.00%
Oruka Therapeutics Gains 21% as Phase 2a Trial Data Exceeds ExpectationsMovers Alert·Apr 27, 2026 at 02:21 PMORKA+3.55%BBH-0.09%
The Nasdaq Biotechnology Index rose over 2.6%, outperforming the broader US stock market. Among constituents, Sarepta Therapeutics surged 34.98%, Summit Therapeutics Plc. rose 15.53%, Enliven Therapeutics increased 14.06%, Upstream Bio gained 12.07%, Taysha Gene climbed 10.90%, Gossamer Bio advanced 10.61%, and Oruka Therapeutics was up 9.80%. Conversely, Aardvark Therapeutics fell 6.10%, ADMA Biologics dropped 15.23%, Anavex Life Sciences declined 34.61%, and Maze Therapeutics fell 35.24%Wallstreetcn·Mar 25, 2026 at 08:50 PMXBI+2.45%TSHA+8.84%
